Assessing the consistency of mass spectrometry, a clinical-laboratory model, and immunohistochemistry in amyloid subtyping: a Brazilian experience
The consistency analysis between the CLM, IHC and MS demonstrated the superiority of MS in amyloid subtyping from tissue biopsies. While the CLM failed in 20% of cases and resulted in inappropriate treatments due to false-positive results, IHC showed very limited diagnostic performance, contrasting with results from reference centers, with less than one-third of cases correctly classified. These findings reinforce the role of MS as a more accurate and cost-competitive method for amyloid subtyping in middle-income countries.
Authors
- Vanderson Rocha (ORCID: https://orcid.org/0000-0003-0094-619X)
- Rodrigo Andrade Schuch (ORCID: https://orcid.org/0000-0002-7183-2969)
- Valdemir Melechco Carvalho (ORCID: https://orcid.org/0000-0002-9816-8615)
- Roberta Shcolnik Szor (ORCID: https://orcid.org/0000-0001-5254-3486)
- Jussara Bianchi Castelli (ORCID: https://orcid.org/0000-0002-8414-4161)
Institutions
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Fleury S.A. (Brazil) (BR)
Publication Details
- Journal
- Clinical Proteomics
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1186/s12014-025-09546-4
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00